Investigation of mechanisms and predictive markers of immune checkpoint inhibitor-induced immune-related adverse events.
No Thumbnail Available
Date
2025-01-30
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Saudi Digital Library
Abstract
bstract:
Introduction: Immune-related adverse events (irAEs) are significant limitations to the use
of immune checkpoint inhibitors (ICIs). Over half of the patients on these medications
experience irAEs, which vary in severity and affected organ. The identification of
susceptible patients through biological biomarkers and genetic variations, along with an
understanding of the immune mechanisms underlying these reactions, is a crucial goal in
this field.
Method: Our study utilized various methods to detect serum biomarkers, including ELISA,
immunohistochemistry, and transcriptomic RNA analyses. We employed in vitro assays to
elucidate the modulating effects of HMGB1 on T-cell and Treg suppression functions that
affect the immune response. Additionally, TaqMan assays and genome-wide association
studies (GWAS) were used to identify single nucleotide polymorphisms (SNPs) of interest.
Results: HMGB1 was significantly elevated in the serum of patients with ICI-induced irAEs,
particularly in those with gastrointestinal (GI) irAEs. Colon biopsies from these patients
showed marked decreases in nuclear staining, indicating cellular death and HMGB1
translocation. Different HMGB1 isoforms varied in their effects on CTLA4 expression on
CD3+ T cells, with dsHMGB1 notably reducing it. The effect of dsHMGB1 on CTLA4
expression in Treg populations showed intra-variability between donors and influenced
the suppression function of Tregs on CD8+ and CD4+ T cells, which relates back to CTLA4
expression on these cells. Unfortunately, SNPs in the main receptor of dsHMGB1
(TLR4/MD2) were not significantly associated with the phenotype. However, female
patients and those with a history of allergic reactions were significantly more likely to
develop irAEs. ARG1 – a marker for MDSC and M2, was found to be significantly expresses
in patients experiencing irAE. In our GWAS 14 snps exceeded our suggestive threshol d,
these SNPs were mapped to regions of genes related to autoimmune disease and cancer.
Discussion: Our findings highlight HMGB1's significant role in mediating immune-related
adverse events (irAEs) in patients treated with immune checkpoint inhibitors. Elevated HMGB1
levels, particularly noted in gastrointestinal irAEs, suggest its potential as a biomarker for irAE
risk. Additionally, the influence of HMGB1 on CTLA4 expression in T cells and Tregs underscores
6
its impact on immune modulation. Despite the lack of significant associations with TLR4/MD2
SNPs, the identification of other genetic variants related to autoimmune conditions hints at a
complex genetic underpinning that warrants further investigation to enhance irAE
management strategies.
Description
Keywords
Immune related adverse events, Immune check point inhibitors, Biomarkers, HMGB1